Cancer Biopsy Market to Reach $92 Billion by 2032, Driven by aging population and advancements in liquid biopsy tests
-
The global cancer biopsy market is expected to reach $92.09 billion by 2032, growing at a 14.8% CAGR from 2023-2032.
-
North America dominated the global cancer biopsy market in 2022 due to its advanced healthcare system and early adoption of technologies.
-
The liquid biopsy segment is expected to see the highest growth rate during the forecast period due to rising physician preference.
-
Kits and consumables made up the largest product segment in 2022, playing a crucial role in biopsy procedures.
-
Key growth drivers include the rising geriatric population and cancer cases globally, as well as advancements in biopsy technologies and methodologies.